Anti-phospholipid Antibody Syndrome, Module 1
LA: Liar in the Lab, Assassin in the Artery. But chromogenic Factor X files the truth.
The Three Fraud Departments
1 · Lupus Anticoagulant (LA) — the Liar
The most important detector, and the most misnamed. Its badge reads anticoagulant, but it lies: in the test tube (in vitro) it slows coagulation, yet in the body (in vivo) it promotes thrombosis. You catch it by the clock — timing how long a transaction takes to clear (a functional clotting assay).
“LA runs on LA time — nothing clears fast.” — LA is the only one of the three measured by time (aPTT, dRVVT); aCL and anti-β2GPI are ELISAs, read rather than clocked, which is why LA alone cannot be drawn on anticoagulation.
“LA lies low — half the time PTT won’t show” — the aPTT is often normal in LA-positive patients (dRVVT may be needed), so a normal aPTT does not rule out LA.
The 3-step detection
Screen: aPTT is prolonged — transactions are slow.
Mixing study: add normal plasma. Normalizes → a factor was missing (deficiency). Stays prolonged → an inhibitor exists. “Mix and Fix — the Factor was missed. Mix and Miss — an Inhibitor exists.”
Confirmatory: flood with excess phospholipid. Phospholipid is the counter every transaction gets signed on, and the Liar works by covering the counters. Open a thousand more and he can’t cover them all — the line clears, proving the blocker was phospholipid-dependent. LA confirmed.
Two practical consequences. (1) Cannot test on anticoagulation — the drugs also slow transactions, making results uninterpretable. Test before starting, or use aCL / anti-β2GPI instead. (2) Falsely elevates the INR — LA interferes with the PT assay too, so the reported INR doesn’t reflect true intensity. Use a chromogenic factor X assay to monitor warfarin in LA-positive patients.
“LA: Liar in the Lab, Assassin in the Artery. But chromogenic Factor X files the truth.” — in-vitro anticoagulant, in-vivo procoagulant; and because LA corrupts the INR, warfarin is monitored with a chromogenic factor X assay.
2 · Anticardiolipin (aCL) — the Card Scanner
Doesn’t time transactions — it scans the cards. anti-cardiolipin reads for one known pattern on the card (cardiolipin, a membrane phospholipid). Because it reads cards instead of timing transactions, it can run while anticoagulation is active.
“aCL = the CARD; the PI (β2GPI) owns the real account” — the card is only plastic; the antibody binds through β2GPI, so the PI (anti-β2GPI, especially domain I) names the true culprit — and is more specific.
Method: ELISA — reads the antibody, not the clock.
Can test on anticoagulation.
2023 titers: moderate 40–79, high ≥80 (GPL/MPL). Highest weight to high-positive IgG (≥80); IgM scores lowest regardless of titer.
Limitation: the most sensitive of the three, but the least specific — the scanner dings on innocent cards, since infections and drugs cause transient false positives.
3 · Anti-β2GPI — the Private Investigator
Tracks the actual ringleader, not just the paper trail. β2-glycoprotein I is the cofactor aPL antibodies need to bind phospholipid — the true antigenic target. Antibodies against it are like confirming the ringleader’s exact address.
Method: ELISA targeting anti-β2GPI.
Most specific antibody for true APS pathogenesis — domain I IgG carries high specificity with only moderate sensitivity.
Domain I antibodies are the 2023 gold standard.
Can test on anticoagulation.
“B2G-PI = Private Investigator” — tracks the actual culprit directly. Most specific because it targets the true antigen.
“Card Scanner flags the crowd, the PI names the boss, the Liar tells you he’ll strike.” — three different axes, one each: aCL is the most sensitive (and noisiest); anti-β2GPI domain I is the most specific (the true antigen); LA is the strongest predictor of thrombosis.
Side by Side
LA and anti-β2GPI are not rivals. LA is a functional assay, not an antibody — the inhibitory activity it detects is largely produced by anti-β2GPI (especially domain I) and anti-prothrombin antibodies. That is also the cleanest reason triple positivity is the worst profile: you are catching the same pathogenic antibody three different ways.
Triple Positivity & the 12-Week Rule
When all three departments flag the same culprit — the Liar, the Card Scanner, and the PI all positive — the case is airtight. That is triple positivity: the highest thrombotic risk at 5–10% per year, and these patients absolutely cannot use DOACs (warfarin only — see Module 3, TRAPS).
The bank never acts on a single report. Transient infections can trigger temporary aPL positivity, so the 2023 criteria require confirmation at least 12 weeks apart. A single positive is never enough to diagnose APS.
The Coagulation Cascade (Why LA Behaves This Way)
Intrinsic pathway (PTT — the regular lane): counts down 12 → 11 → 9 → 8. LA interferes here (phospholipid-dependent step). Heparin acts on this lane.
Extrinsic pathway (PT — the express lane): Factor 7 stands alone. PT↑ with normal PTT = Factor VII problem.
Common pathway: both lanes merge at X → prothrombin (II) → thrombin → fibrin, crosslinked by XIII.
Vitamin K–dependent: II, VII, IX, X + Protein C & S.
“Going to WAR with your EX over the ProperTy” — WAR = warfarin, EX = extrinsic, PT/INR is what you track.
Test Yourself
Q1: A 32-year-old woman with recurrent DVTs has a prolonged aPTT. The mixing study does NOT correct. Next step?
Answer: Failure to correct means an inhibitor is present (“Mix and Miss”). Proceed to the confirmatory step — add excess phospholipid; normalization confirms lupus anticoagulant. Also send aCL and anti-β2GPI (these can be drawn on or off anticoagulation), and re-confirm any positive at ≥12 weeks before diagnosing APS.
Q2: Which aPL profile carries the highest thrombotic risk, and what therapy does it mandate?
Answer: Triple positivity — lupus anticoagulant + anticardiolipin + anti-β2GPI all positive. Highest risk (5–10%/year). It mandates warfarin; DOACs are contraindicated (TRAPS trial).
Summary
Three aPL tests / three fraud roles: LA = the Liar (functional assay), aCL = the Card Scanner (ELISA), anti-β2GPI = the PI (ELISA).
Card Scanner flags the crowd, the PI names the boss, the Liar tells you he’ll strike — aCL most sensitive, anti-β2GPI domain I most specific, LA strongest thrombosis predictor.
LA runs on LA time — the only one measured by the clock; the other two are read on an ELISA.
LA lies low — a normal aPTT does not rule out LA; dRVVT may be needed.
LA: in-vitro anticoagulant, in-vivo procoagulant.
Mix and Fix — the Factor was missed; Mix and Miss — an Inhibitor exists.
Excess phospholipid confirms LA — the inhibitor is phospholipid-dependent.
LA lies on the INR — use a chromogenic factor X assay for warfarin monitoring.
The Card leads to the PI — aCL binds via β2GPI; anti-β2GPI (domain I) is the most specific target.
Triple positivity = highest risk (5–10%/year) = warfarin only.
Always confirm at ≥12 weeks — never diagnose APS on a single positive test.
Sources: 2023 ACR/EULAR APS Classification Criteria (Arthritis Rheumatol 2023;75:1687) · de Laat, β2GPI-dependent LA & thrombosis (Blood 2004;104:3598) · anti-domain I meta-analysis (PMC12056313).
